Combining VEGFR tyrosine kinase inhibitors and PD-1/PD-L1 inhibitors versus VEGFR tyrosine kinase inhibitors monotherapy in renal cell carcinoma: a target trial emulation
Discuss this preprint
Start a discussion What are Sciety discussions?Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Importance
Combinations of VEGFR tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs), such as antibodies to programmed cell death-1 (PD-1), or to its ligand PD-L1, are now first-line standard of care for renal cell carcinoma (RCC), but the pivotal clinical trials excluded patients with common comorbidities, leaving their real-world effectiveness uncertain.
Objective
To determine whether adding PD-1/PD-L1 inhibitors to VEGFR-TKIs therapy is associated with improved overall survival in a real-world RCC cohort.
Design, Setting, and Participants
This retrospective cohort study used a target trial emulation framework and real-world electronic health records data from the University of Florida Health Integrated Data Repository (IDR). Data was analyzed from September 2009 through June 2023. Adult patients (≥18 years) with confirmed RCC and at least one VEGFR-TKIs prescription were eligible. The date of the first VEGFR-TKIs prescription was defined as the index date, and patients were followed for up to 24 months. Variable-ratio propensity score matching (up to 2:1) across 13 baseline covariates was used to emulate randomized treatment assignments. Of 107,783 patients screened, 387 met eligibility criteria, and 319 remained in the matched cohort.
Exposures
VEGFR-TKIs monotherapy (control group) versus VEGFR-TKIs combined with PD-1/PD-L1 inhibitors (experimental group).
Main Outcomes and Measures
Overall survival (OS), analyzed by weighted Kaplan-Meier estimation, cluster-robust Cox regression, and restricted mean survival time (RMST) at τ = 24 months, prespecified given anticipated non-proportional hazards.
Results
Among 319 matched patients (mean [SD] age, 62 [12] years; 76% male), 107 deaths occurred (33.5%). Twelve-month OS was higher in the combination arm (81.8%; 95% CI, 74.7–89.6%) than VEGFR-TKIs monotherapy (68.1%; 95% CI, 61.1–76.0%), converging by 24 months (61.1% vs 56.7%). The Cox hazard ratio was 0.718 (95% CI, 0.484– 1.064; P = 0.0986). RMST was 2.79 months greater with combination therapy (95% CI, 0.93–4.65; P = 0.0033).
Conclusions
Adding PD-1/PD-L1 inhibitors to VEGFR-TKIs therapy was associated with a statistically significant and clinically meaningful gain in restricted mean survival, supporting the real-world generalizability of combination therapy and the importance of appropriate treatment effect measures under non-proportional hazards.
